|Articles|October 1, 1998

Clinical and Economic Considerations of Antimicrobial Use
Volume 4
Issue 11 Suppl

Pharmacoeconomic Impact of Appropriate Clinical Pathways

Author(s)N. Stephen Ober, MD

Download PDF: Pharmacoeconomic Impact of Appropriate Clinical Pathways

Articles in this issue

over 27 years ago

Article

Optimizing Antimicrobial Therapy and Emerging Pathogens

over 27 years ago

Article

Participating Faculty

over 27 years ago

Article

Introduction

over 27 years ago

Article

Mechanisms and Current Rates of Resistance

over 27 years ago

Article

Influence of Antibiotics on the Normal Flora

over 27 years ago

Article

Therapeutic Pathways for Antimicrobial Use: General Overview

over 27 years ago

Article

Therapeutic Pathways for Antimicrobial Use: Pediatric Issues

over 27 years ago

Article

Cost Savings of Clarithomycin Compared With Erythromycin or Cefaclor in the Treatment of Lower Respiratory Tract Infection: Results of a Randomized, Multicenter Study

over 27 years ago

Article

Developing Cost-Effective Guidelines for the Appropriate Use of Antimicrobial Therapy in Respiratory Tract Infection

over 27 years ago

Article

CME Quiz

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Pharmacoeconomic Impact of Appropriate Clinical Pathways

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

More Potent and Tolerable, Azenosertib Advances as the Leading WEE1 Inhibitor

Health Care Spending to Hit $9 Trillion by 2034, According to New Analysis

Treatment Burden, End-of-Life Symptom Gaps in Multiple Myeloma